U
ORKA

UBS’s Oruka Therapeutics ORKA Stock Holding History

UBS’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2
Closed -$4.18K – 10827
2014
Q2 		$5K Buy
+2
New +$4.65K ﹤0.01% 9541
2014
Q1 		– Hold
0
– – – 10882
2013
Q4 		– Hold
0
– – – 10824
2013
Q3 		– Sell
-1
Closed -$2.08K – 10762
2013
Q2 		$3K Buy
+1
New +$3.05K ﹤0.01% 9645

Other funds holding ORKA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS's ORKA Position: Q3 2014 in Review

UBS sold out of Oruka Therapeutics (ORKA) in Q3 2014, closing a stake of 2 shares — an estimated $4.18K sold.

UBS first reported a position in ORKA in Q2 2013 and held it in 2 quarters. The position peaked at $5K in Q2 2014. 14 funds tracked by Wall St. Rank hold ORKA as of Q3 2014.

  • UBS reported no remaining Oruka Therapeutics position as of Q3 2014 after selling out during the quarter.
  • UBS sold 2 Oruka Therapeutics shares in Q3 2014, an estimated $4.18K.
  • UBS first reported a position in Oruka Therapeutics in Q2 2013 and held it in 2 quarters.
  • UBS's Oruka Therapeutics position peaked at $5K in Q2 2014.
  • 14 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.